By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Am Klopferspitz 19

Martinsried  Munchen  82152  Germany
Phone: 49-0-89-30-90-50680 Fax: 49-0-89-30-90-506868



Company News
SuppreMol's Clinical Data In SLE For Its Lead Product SM101 Accepted For Presentation At The 2014 ACR / ARHP Annual Meeting In Boston 9/9/2014 9:29:23 AM
SuppreMol Appoints Industry Expert Klaus Schollmeier as CEO 4/3/2013 10:05:13 AM
SuppreMol Begins Development of Anti-IL-3 Monoclonal Antibody to Diagnose and Treat Early Stage Rheumatoid Arthritis 7/27/2012 10:15:08 AM
SuppreMol Releases Positive Interim Phase Ib/IIa Results on SM101 in Primary Immune Thrombocytopenia (ITP) Trials 3/15/2012 9:58:07 AM
SuppreMol Employs Protagen AG Biomarkers in SLE Study 8/2/2011 10:05:31 AM
SuppreMol Receives U.S. Orphan Drug Designation for SM101 4/23/2010 1:52:15 PM
SuppreMol Initiates Phase Ib/Iia Clinical Trial With Its Lead Candidate SM101 4/14/2010 3:27:34 PM
SuppreMol Appoints Dr. Robert Phelps as Head of Business Development & Licensing 2/8/2010 12:07:39 PM
SuppreMol Announces Start of Phase I Clinical Trial with its lead program SM101 5/11/2009 1:43:50 PM
SuppreMol Announces Expansion of its Management Team and Board Changes 10/21/2008 3:28:38 PM